Understanding the molecular mechanisms underlying CDKN1B dysregulation and its impact on breast cancer progression is important to improve treatment strategies for breast cancer by developing potential therapeutic targets and identifying its role as a prognostic marker. Here, CDKN1B is linked to breast carcinoma.